T-16-02: Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B.
| Autor: | Klamroth, R., Bonner, A., Yan, S., Monahan, P., Szafranski, K., Herepath, M., Zhang, X., GomezHaemophilia Centre and Thrombosis Unit, Royal FreeLondon NHS Foundation Trust, London, UK, K. |
|---|---|
| Zdroj: | Hämostaseologie; 2023 Supplement, Vol. 43, pS68-S69, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|